Samsung Biologics to acquire PolyPeptide for $1.8 bil.

Samsung Biologics said Monday it will acquire Swiss peptide drug manufacturer PolyPeptide Group through an all-cash public tender offer valued at approximately 1.46 billion Swiss francs ($1.8 billion), marking its largest overseas acquisition as it expands beyond antibody manufacturing into peptide therapeutics.

The Korean contract development and manufacturing organization (CDMO) will offer 44.31 Swiss francs per share for all outstanding shares of PolyPeptide, representing a 40 percent premium to the company's unaffected closing price before acquisition rumors emerged in April.

The transaction, expected to close toward the end of 2026, is subject to shareholder approval, regulatory clearances and other customary conditions.

Samsung Biologics must secure at least a two-thirds acceptance rate from shareholders.

PolyPeptide's largest shareholder, which owns about 55.7 percent of the company, has already agreed to tender its stake.

PolyPeptide's board of directors unanimously recommended that shareholders accept the offer, saying the acquisition provides an attractive outcome for investor ...